Institutions / Saturn V Capital Management LP
Saturn V Capital Management LP
CIK 1964437 · Institution · as of Dec 31, 2025
Portfolio value
$544.90M
Positions
20
As of
Dec 31, 2025
Top holdings
Dec 31, 2025
| Company | Value | % of portfolio |
|---|---|---|
| Abivax SA | $87.55M | 16.1% |
| Amylyx Pharmaceuticals, Inc. | $54.32M | 10.0% |
| Cogent Biosciences, Inc. | $43.23M | 7.9% |
| Jazz Pharmaceuticals PLC | $42.17M | 7.7% |
| Vaxcyte, Inc. | $36.86M | 6.8% |
| Dyne Therapeutics, Inc. | $34.99M | 6.4% |
| Pharvaris N.V. | $31.64M | 5.8% |
| Celcuity Inc.CELC | $31.63M | 5.8% |
| Alumis Inc.ALMS | $30.61M | 5.6% |
| Disc Medicine, Inc.IRON | $23.70M | 4.3% |
| X4 Pharmaceuticals, Inc | $23.20M | 4.3% |
| Monopar Therapeutics Inc.MNPR | $21.27M | 3.9% |
| Invivyd, Inc. | $19.11M | 3.5% |
| Ocular Therapeutix, Inc | $18.27M | 3.4% |
| Immix Biopharma, Inc. | $15.69M | 2.9% |
| Oculis Holding AG | $10.32M | 1.9% |
| Inhibikase Therapeutics, Inc. | $7.91M | 1.5% |
| Centessa Pharmaceuticals PLC | $7.07M | 1.3% |
| Ovid Therapeutics Inc. | $4.08M | 0.7% |
| Inventiva SA | $1.32M | 0.2% |
Activity
Dec 31, 2025
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.No quarter-over-quarter changes yet — position changes appear once we've ingested two consecutive 13F filings for this manager. We currently hold 1 quarter of holdings.